Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

A. Fennell, Dean; Ewings, Sean; H. Ottensmeier, Christian; Califano, Raffaele; G. Hanna, Gerard; Hill, Kayleigh; Danson, Sarah; Steele, Nicola; Nye, Mavis; Johnson, Lucy; Lord, Joanne; Middleton, Calley; W. Szlosarek, Peter; W. Chan, Sam; Gaba, Aarti; Darlison, Liz; Wells-Jordan, Peter; Richards, Cathy; Poile, Charlotte; Lester, J.F.; Griffiths, Gareth; Price, Gillian; Shaw, Paul; Cave, Judith; Naik, Jay; Ford, Amy; Geldhart, Tom; Dancey, Gairin; Papadatos, Dionysis; Polychronis, Andy; Jankowska, Petra; Scott, Angela; Gardiner, Jill; Cominos, M.; Campbell, Lynn; MacGregor, Carol; Mullholand, Lois; Chitnis, Meenali; Dougherty, Gary

doi:10.1016/s1470-2045(21)00471-x

Public

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Published in The Lancet Oncology • Oct 15, 2021

Authors:

Dean A. Fennell

Sean Ewings

Christian H. Ottensmeier

Abstract

BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. M...

Subject

Nivolumab

Medicine

Peritoneal mesothelioma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!